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A B S T R A C T
Statins present a number of beneficial effects on endothelial function and atheroscle-
rotic plaque, modulating oxidative stress and inflammation. The benefits of long-term 
statin treatment in the entire spectrum of atherosclerotic vascular disease can largely 
be explained by its cholesterol-lowering effects and the associated reduction of the 
progression of atherosclerosis. The short-term benefits of statin use are most likely 
due to their non-lipid, pleiotropic effects. Myocardial injury during percutaneous 
coronary intervention (PCI) occurs in 10-40% of cases and is often characterized by 
a slight increase in the markers of myocardial necrosis, sometimes without symptoms, 
electrocardiographic changes or impairment of cardiac function. Periprocedural myo-
cardial infarction is associated with a worse outcome on long-term follow-up. Several 
randomized trials have suggested a beneficial effect of pre-treatment with statins in 
the outcome of the procedure. Myocardial protection by statin pre-therapy in PCI 
has been studied in several trials published over the last decade. The mechanisms 
underlying the beneficial pleiotropic effects of statins may be an anti-inflammatory 
action reducing myocardial injury necrosis due to microembolization, an improve-
ment in endothelial function on microcirculation, and direct myocardial protection. 
This article reviews the major randomized trials which have studied the use of statins 
as pre-treatment in PCI and explores future perspectives.
I n T R o d u C T I o n
The increasing burden of vascular disease risk factors has led to an increase in the 
incidence of coronary artery disease (CAD). According to the World Health Organiza-
tion (WHO), an estimated 7.2 million people died from CAD in 2004, representing 
12% of all global deaths and making CAD a leading cause of morbidity and mortality 
in the developed,1 as well as in developing countries. Improvements in the medical 
and surgical care of patients suffering from heart disease have led to a large number 
of people surviving an acute coronary event. Compared with individuals without 
CAD, those with previous CAD have a greater absolute risk of recurrent coronary 
events and hence, derive greater absolute benefits from conventional therapies, such 
as lipid lowering and blood pressure control. It is well established that patients with 
dyslipidemias are at an increased risk of developing atherosclerosis and subsequent 
CAD. The availability of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
reductase inhibitors (“statins”) has revolutionized the treatment of lipid abnormalities. 
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Not surprisingly, the decade of the 1990s has been termed the 
“statin decennial” in the history of CAD prevention.2
T h e  R o l e  o f  S T A T I n S  I n  C o R o n A R y  A R T e R y 
d I S e A S e
In patients without cardiovascular disease, a meta-analysis 
of 7 landmark studies (WOSCOPS, AFCAPS/ TexCAPS, 
PROSPER, ALLHAT-LLT, ASCOT-LLA, HPS, CARDS) 
published in 2006, showed that statin therapy decreases the 
incidence of major coronary and cerebrovascular events and 
revascularizations but not CAD or overall mortality.3 On the 
other hand, in subjects with known cardiovascular disease, 
statin therapy has proved to be not only beneficial but also 
cost effective. Several studies have shown that statins improve 
coronary and cerebrovascular disease outcomes and reduce 
mortality, in patients with established cardiovascular disease 
(i.e., secondary prevention).4-7
The secondary preventive benefits of atorvastatin are 
confirmed in various clinical settings, including established 
CAD. Statin therapy was associated with a 20–42% reduction 
in long-term mortality.8 The IDEAL (Incremental Decrease 
in End Points Through Aggressive Lipid Lowering)9 and 
TNT (Treating to New Targets)10,11 trials demonstrated the 
preventive efficacy of atorvastatin in patients with stable CAD.
The benefits of long-term statin treatment can largely be 
explained by its cholesterol-lowering effects (especially the 
reduction of low-density lipoprotein-LDL cholesterol) and the 
associated retardation of the progression of atherosclerosis.12,13 
Mechanisms related to the stability of the atherosclerotic 
plaque may be important in determining clinical outcomes 
in the early post- acute coronary syndrome (ACS) period. 
The short-term benefits of statins are most likely due to their 
non-lipid, pleiotropic effects. Many in vitro as well as in vivo 
studies have demonstrated that statins acutely decrease the 
inflammatory response, improve endothelial function, reduce 
adhesion molecules expression and adhesiveness of leukocyte 
to vascular endothelium, increase plaque stability, decrease 
platelet aggregation and thrombus formation, decrease apop-
tosis, increase stem cell availability and function and have 
direct protective effects on myocardial cells.8,14-16 A consider-
able number of studies published in early-mid 2000s confirmed 
the beneficial pleiotropic effects of statins on several clinical 
settings including patients undergoing non-cardiac vascular 
surgery,17 coronary artery bypass graft surgery (CABG)18 as 
well as patients with ACS. Especially in ACS patients, sev-
eral studies showed that not only it might be advantageous 
to start a statin early after hospital admission but also that 
intensive statin therapy using higher dose of either simvastatin 
(A-to-Z19) or atorvastatin (MIRACL,20 PROVE-IT TIMI-
2221) leads to significantly reduced clinical outcomes after 
4 months (A-to-Z, MIRACL) with the benefit starting at 30 
days (PROVE-IT TIMI-22). Moreover, PCI-PROVE IT,22 a 
substudy of PROVE-IT TIMI-22, published in 2009, showed 
that intensive atorvastatin therapy in patients undergoing PCI, 
results in significant reduction in target vessel revasculariza-
tion (TVR) compared to standard statin therapy, an outcome 
irrelevant to on-treatment LDL-cholesterol when multivariate 
logistic regression analysis was performed.
T h e  u S e  o f  S T A T I n S  P R I o R  T o  P e R C u T A n e -
o u S  C o R o n A R y  I n T e R v e n T I o n  ( P C I )
Over the last 20 years there is an increasing number of 
percutaneous coronary intervention (PCI) procedures per-
formed for either stable CAD or ACS. An increase in cardiac 
enzyme levels is observed in 5-30% of patients undergoing 
PCI.23 A considerable number of cases fulfill the criteria (CK-
MB>3 x upper limit of normal-ULN) for post-PCI myocardial 
infarction (MI) (type 4a) according to the latest guidelines,24 
indicating a varying extent of peri-procedural myocardial 
necrosis. Troponin and CK-MB elevation is not uncommon 
after PCI as a result of iatrogenic controlled plaque rapture 
and the subsequent release of many vasoactive substances 
to the circulation leading to vasoconstriction, endothelial 
dysfunction, myocardial ischemia and necrosis.14 Moreover, 
a considerable number of PCIs are complicated with vessel 
dissection, compromise of side branches, thrombus formation, 
distal embolization, or the no-reflow phenomenon.25 Due to 
the fact that measurement of cardiac biomarkers after PCI 
is quite simple, peri-procedural MI has been established as 
the most suitable quality indicator for PCI care.26 Since the 
early ‘90s, many researchers have examined the impact and 
the clinical significance of cardiac biomarker elevation after 
PCI. Although some early studies, using low cutoff concentra-
tions of cardiac enzymes after PCI, had not shown significant 
correlation with an increased incidence of composite adverse 
events,27,28 the majority of the studies conducted over the last 
10 years indicate that while minimal increases in troponin 
after PCI may be benign, a significant rise in CK-MB, espe-
cially >5×ULN, appears linked to increased cardiac morbidity 
and mortality.29-35 Therefore, a variety of interventions were 
proposed and tested in order to prevent periprocedural MI, 
including use of ticlopidine,36 GpIIb/IIa inhibitors,37-40 beta 
blockers,41 high-dose of clopidogrel42 and statins. Among 
them, pre-treatment with statins is the strategy that is most 
frequently followed.
R A n d o m I z e d  T R I A l S  ( T A B l e  1)
In the beginning of the previous decade, two studies 
showed a decrease in infarct size following an acute statin 
load given before ischemia43 or before reperfusion,44 followed 
by several other observational studies that demonstrated a 
significant benefit of statin pre-therapy on peri-procedural 
elevation of cardiomarkers.45-48 The first randomized trial 
scheduled to evaluate the effects of statins before PCI on pre-
venting myocardial damage was the ARMYDA (Atorvastatin 
for Reduction of Myocardial Damage During Angioplasty) 
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TABle 1. Randomized trials of Statin-Loading Before PCI
Study year n Trial
Clinical 
status
Previous 
Statin 
use Statin used dose
Initiation 
of therapy 
before PCI end point P value
STATIN-
STEMI59
2010 171 RCT STEMI No Atorvastatin 80 mg vs 
10 mg
Emergency 
Department
30-day MACE
CTFC
Myocardial Blush 
Grade
ST-elevation 
resolution
NS
0.01
0.02
0.01
Yun et al56 2009 445 Open 
label
NSTE-ACS No Rosuvastatin 40 mg 7-25h Peri-procedural MI
30-day MACE
<0.05
0.002
NAPLES II52 2009 668 RCT Stable 
Angina 
(53%)
No Atorvastatin 80 mg <24h Peri-procedural MI
In hospital MACE
<0.05
0.029
ARMYDA-
RECAPTURE53
2009 393 RCT Stable 
Angina
Yes Atorvastatin 80 mg 80 mg 12 h 
and 40 mg 
before PCI
30-day MACE
Peri-procedural MI
0.037
<0.05
Veselka et al.54 2009 200 RCT Stable 
Angina
No Atorvastatin 80 mg 48 h Peri-procedural MI NS
Jia et al.55 2009 228 RCT NSTE-ACS No Simvastatin 80 mg vs. 
20 mg 
Seven days Peri-procedural MI
TFG
CTFC
TMPG
0.003
<0.05
<0.001
0.001
ARMYDA-
ACS51 
2007 171 RCT NSTE-ACS No Atorvastatin 80/40 mg 80 mg 12 h 
and 40 mg 
before PCI
30-day MACE
Peri-procedural MI
0.01
<0.05
Chyrchel et al.50 2006 140 Open 
Label
NSTE-ACS No Atorvastatin 80 mg 3 days Long-term:
MI
Death+MI
Death+MI+PCI
0.03
0.013
0.006
ARMYDA49 2004 153 RCT Stable 
Angina
No Atorvastatin 40 mg 7 days Peri-procedural MI
30-day MACE
<0.05
0.025
Briguori et al.23 2004 451 Open 
Label
Elective 
PCI
No All 80 mg ≥3 days (84% 
>2weeks)
Peri-procedural MI 0.012
ACS = acute coronary syndrome; MACE = major adverse cardiac event; PCI = percutaneous coronary intervention; RCT = randomized controlled 
trial; STEMI = ST-elevation Myocardial Infarction; CTFC = corrected TIMI frame count; TFG = TIMI flow grade; TMPG = TIMI myocardial 
perfusion grade
trial.49 The investigators randomized 153 stable angina patients 
to atorvastatin 40 mg/day for seven days before PCI or to 
placebo. All patients had a positive stress test and were statin-
naive, although 40% of them were hypercholesterolemic. 
The primary end-point of the trial was the incidence of MI, 
defined as post-PCI increase of CK-MB >2 x the upper limit 
of normal. Investigators found that treatment with atorvastatin 
40 mg was significantly associated with reductions in CK-MB 
(5% vs 18%, p=0.025). In addition, post-PCI peak values of 
CK-MB (2.9 ng/ml vs 7.5 ng/ml, p=0.007), troponin I (0.09 
ng/ml vs 0.47 ng/ml, p=0.0008) and myoglobin (58 ng/ml vs 81 
ng/ml, p=0.0002) were significantly lower in the statin-treated 
patients than in those who received placebo.
In the same year, Briguori et al23 randomized 451 statin-
naive patients to different types and doses of statins, 17±8 
days prior to elective PCI in order to examine the impact of 
statin administration on periprocedural myocardial infarction. 
The results were similar with the ARMYDA trial. CK-MB 
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control group (p=0.014). A similar effect was also observed 
with troponin I levels (26.6% vs 39.1%, p<0.001). A post-hoc 
analysis suggested that the cardioprotective effect of atorvas-
tatin was more pronounced in the subgroup of patients with 
baseline high levels of CRP. Finally, there was a significant 
reduction in all in-hospital events including death, MI and 
repeated revascularization (10% vs 15.7%, p=0.029).
While the previous ARMYDA trials enrolled statin-naive 
patients, in ARMYDA-RECAPTURE trial53 researchers ran-
domized a group of patients pretreated with statins, present-
ing with stable angina and NSTE-ACS to either atorvastatin 
“reload” or to placebo. The “reload” patients received 80 mg 
of atorvastatin 12 hours prior to PCI, followed by an additional 
40 mg approximately 2 hours before the procedure. All pa-
tients were treated with atorvastatin 40 mg after PCI. Of the 
457 patients who were randomized, 383 who underwent PCI 
were analyzed: At 30 days, the rate of major adverse cardiac 
events, a composite of cardiac death, MI and target vessel 
revascularization, was significantly lower among patients re-
loaded with atorvastatin prior to PCI (3.4% vs 9.4%, p=0.045). 
This benefit was primarily driven by a 2.4-fold reduction in 
the incidence of periprocedural MI (3.7% vs 8.9%, p=0.056), 
defined as elevation of CK-MB and troponin I >3×ULN. 
Logistic regression analysis also revealed a significant benefit 
on 30-day MACE especially in patients presenting with ACS 
(3.3% vs 14.8%, p=0.015) as compared to a non-significant 
difference in patients with stable angina (4% vs 4.9%, p=0.98).
A Czech study by Veselka et al54 examined once more 
the effect of high-dose atorvastatin two-day pretreatment in 
200 statin-naive patients presenting for elective PCI due to 
stable angina. This specific study did not find a statistically 
significant difference between the two groups concerning 
periprocedural MI, whether CK-MB (10% vs 12%, p=0.70) 
or troponin I (17% vs 16%, p=0.54) was used as an indicator.
The first randomized control trial not to use atorvastatin 
was published by Jia et al.55 The authors investigated the role 
of an intensive simvastatin regimen (80 mg vs 20 mg) seven 
days before a programmed PCI after an ACS. A total of 228 
patients were randomized and a variety of variables were 
assessed before and after stent deployment. The authors 
concluded that intensive simvastatin treatment reduced CK-
MB-related periprocedural MI (15.9% vs 27.8%, p=0.003) 
as well as improved myocardial blood perfusion as measured 
by Thrombolysis in Myocardial Infarction (TIMI) flow grade 
(TFG) (p<0.05), corrected TIMI frame count (CTFC) 
(p<0.001) and TIMI myocardial perfusion grade (TMPG) 
(0.001) of the intervened vessel.
Yun et al56 examined whether a single high-dose rosuv-
astatin loading is beneficial on the outcome of patients with 
ACS who undergo PCI. A total of 445 patients presenting 
with NSTE-ACS and planned to early invasive strategy were 
randomized to receive either a 40 mg rosuvastatin loading 
16±5 hours (range 7–25 hours) before PCI or placebo. The 
elevation >5 times ULN occurred in 8% of the patients in the 
statin group and in 15.6% in the control group (p=0.012; odds 
ratio- OR=0.47; 95% confidence intervals-CI=0.26–0.86), 
while CK-MB elevation >3 times ULN was not significant. 
Moreover, cardiac troponin I elevation >5 times ULN oc-
curred in 23.5% of the patients in the statin group and in 32% 
in the control group (p=0.043; OR=0.65; 95% CI 0.42–0.98). 
The authors concluded that pre-procedural statin therapy 
reduces the incidence of large non-Q-wave myocardial infarc-
tion after PCI.
In a Polish study by Chyrchel et al,50 140 consecutive pa-
tients presenting with non-ST elevation ACS (NSTE-ACS), 
increased C-reactive protein (CRP) levels and no history 
of statin use, were randomized either to receive 80 mg of 
atorvastatin for 3 days prior to intervention or placebo. The 
incidence of primary endpoint of major adverse cardiac events 
(MACE) (death, MI, repeat PCI) during long-term follow-up 
was significantly lower in patients pretreated with a high load-
ing dose of atorvastatin (2.32% vs 14.8%, p=0.013).
The subsequent ARMYDA-ACS study51 was the first to 
include patients presenting with NSTE-ACS. In this study, 
171 statin-naive patients were randomized either to a short-
term pre-treatment strategy of high dose atorvastatin (80 
mg) given 12 hours pre-PCI followed by atorvastatin 40 mg 
immediately prior to the procedure, or to placebo. Statin use 
reduced 30-day incidence of the composite endpoint of death, 
MI, and target vessel revascularization-TVR at 30 days by 
88% compared to placebo (17% vs 5%, p=0.01). The benefit 
on major cardiac events was largely driven by a significant 
reduction in periprocedural MIs defined as a CK-MB level 
>2×ULN for patients with normal preprocedural CK-MB or 
a two-fold increase for patients with elevated baseline levels 
of CK-MB (7% vs 27%, p=0.001). Given the results, the in-
vestigators supported the short-term pretreatment with high 
dose atorvastatin (80+40 mg) in patients with NSTE-ACS 
planned for early invasive strategy.
During 2009, more prospective randomized trials provid-
ing new evidence on the effect of high-dose acute adminis-
tration of statins prior to PCI were published. The Naples II 
trial52 assessed whether a single high loading dose (80 mg) of 
atorvastatin may reduce the rate of periprocedural MI among 
a group of 1385 statin-naive patients undergoing elective PCI. 
The patients were randomized to receive either 80 mg atorv-
astatin or usual care without additional atorvastatin the day 
before the procedure (no placebo control was present in the 
study). There were 668 patients who underwent PCI and stent-
ing in de novo lesions of native coronary artery included in the 
analysis. At 30 days, treatment with atorvastatin significantly 
reduced the risk of periprocedural MI as defined by elevations 
of CK-MB and cardiac troponin I. The primary end point of 
the study, a CK-MB level 3×ULN alone or with chest pain or 
ST-T abnormalities, was reached by 9.5% of patients in the 
active treatment group compared to 15.8% of patients in the 
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primary end point was the occurrence of periprocedural MI, 
defined as a post-procedural increase of CK-MB >2×ULN 
in patients with normal baseline enzyme levels. In patients 
with elevated baseline levels of CK-MB, MI was defined as 
a subsequent increase of more than 2-fold in CK-MB from 
baseline value and an additional increase in second sample. 
Myocardial infarction by CK-MB elevation was detected after 
PCI in 11.4% of patients in the control group and in 5.8% of 
those in the rosuvastatin group (p=0.035). Moreover, after 
rosuvastatin 40 mg loading, high sensitivity-CRP (hsCRP) 
levels were less elevated than in patients without rosuvastatin 
loading (p<0.001).
The same authors just published the results from the12-
month follow-up of the above patients57 that show a reduced 
incidence of MACE (20.5% vs. 9.8%, p=0.005) and death 
and non-fatal MI (p=0.021) indicating a beneficial long-term 
effect of statin pretreatment.
In a meta-analysis58 including 2804 patients from 10 ran-
domized control trials (four studies included ACS patients 
and the remaining six studies included patients scheduled for 
elective PCI), the authors concluded that statins administered 
before PCI significantly reduce post-procedural MI (7.5% vs. 
13.3%, p<0.0001) while repeat revascularization was non-
significantly reduced.
In 2010, STATIN STEMI trial59 was published being the 
first one to examine the effect of statin preloading in a primary 
PCI setting after a ST-elevation MI (STEMI). A total of 171 
patients presenting with STEMI were randomized to receive 
either 80 mg atorvastatin or 10 mg atorvastatin before PCI, 
while all patients continued with a 10-mg regimen after PCI. 
Although high-dose (80 mg) atorvastatin treatment before 
primary PCI was associated with a 46% reduction in the pri-
mary composite endpoint of 30-day MACE, including death, 
non-fatal MI and target vessel revascularization, compared 
with low-dose atorvastatin, this result did not reach statistical 
significance. The authors attributed this finding to the fact 
that the study was not nearly powered enough to assess this 
end-point, because of the small number of events occurring in 
both groups. Nevertheless, the same study showed significantly 
improved immediate coronary flow after primary PCI as mea-
sured by CTFC (p=0.01), myocardial blush grade (p=0.02) 
and ST-elevation resolution at 90 min after PCI (p=0.01), 
indicating better microvascular myocardial perfusion.
P e R S P e C T I v e
According to the studies presented above, there is a 
general consensus that statin use before the initiation of PCI 
is associated with decreased incidence of peri-procedural 
myonecrosis compared with placebo. Periprocedural CK-MB 
elevation is independently associated with an increased risk of 
mortality and other early adverse outcomes in patients with 
NSTE-ACS, but a definite cause and effect relationship is not 
well established.60 Most of the randomized controlled trials 
showed that statin-naive patients undergoing either elective 
PCI for chronic stable angina or semi-urgent PCI for ACS, 
enjoy a significant reduction in peri-procedural MI as well 
as in major adverse cardiac events (MACE) following oral 
atorvastatin loading regimens.
Following several non-randomized clinical trials indicating 
that prior statin use improves outcomes in patients undergoing 
PCI,61,62 the ARMYDA-RECAPTURE trial moved forward 
indicating that a short-term pre-treatment with high-dose 
atorvastatin load before PCI improves outcomes in patients 
already receiving chronic statin therapy. An interesting point 
in this study was that the reduction in periprocedural MIs was 
observed among patients with ACS whereas no benefit was 
seen among patients with stable angina. The investigators of 
Naples-II study suggest that among clinically stable patients 
undergoing elective PCI, the benefit of acute atorvastatin 
loading is present in patients with elevated CRP levels and 
not in patients with normal CRP. Similarly, in the recent 
study conducted by Yun et al53 the hsCRP peak after PCI was 
significantly lower in the rosuvastatin loading group than in 
the control group. Additionally, the findings derived by previ-
ous trials, such as the PROVE-IT TIMI-22 trial, also imply 
that the anti-inflammatory role of atorvastatin is probably 
responsible for the early benefit observed within 30 days of 
an ACS in patients enrolled in comparison to 4 months seen 
in MIRACL and A-to-Z trials.
From all the above we conclude that survival benefit 
with statin pretreatment is dependent on the periprocedural 
inflammatory status and the periprocedural myocardial 
injury observed is well correlated with subsequent vascular 
inflammation.20 Thus, the overall beneficial effect of statins 
in cardiovascular disease can be explained not only by their 
lipid-lowering potential but also by their pleiotropic effects, 
i.e. non-lipid-related mechanisms that may potentially improve 
outcome after a PCI.63
Anti-inflammatory effects of chronic treatment with 
atorvastatin have been already documented in a randomized 
controlled trial in patients with rheumatoid arthritis.64 Statins 
may also be protective against the development of rheumatoid 
arthritis in patients with hyperlipidemia,65 while simvastatin 
has antiatherosclerotic activity beyond its plasma cholesterol–
lowering activity owing to anti-inflammatory effects similar 
to indomethacin.66 Early fluvastatin administration decreases 
dose-dependently the serum concentrations of hs-CRP and 
tumor necrosis factor (TNF-α) of patients with ACS indicating 
a strong anti-inflammatory effect beyond the lipid lowering67 
and high dose atorvastatin (80 mg) initiated at the time of coro-
nary artery stent implantation reduces the acute inflammatory 
response measured by CRP, and six-month clinical events. In 
patients with NSTE-ACS, the anti-inflammatory activity of 
statins in CRP and interleukin 6 (IL-6) concentrations may 
occur as early as a few hours after the first administration be-
fore the levels of circulating lipids are significantly affected.68
PRE-PCI STATIN LOADING
75
As we have already mentioned, a systemic inflammatory 
response takes place during PCI as a result of iatrogenic plaque 
rupture. Coronary angioplasty is followed by a transient in-
crease in adhesion molecule levels due to local endothelial ac-
tivation/damage,69 a point that was studied in the ARMYDA-
CAMs subanalysis.70 This study demonstrated that procedural 
protection in the atorvastatin arm was paralleled by reduction 
of PCI-induced endothelial activation, as expressed by signifi-
cant attenuation in the increase of intercellular cell adhesion 
molecule-1 and E-selectin levels at 24 hours after interven-
tion. Surprisingly, while the cardioprotective effect of statins 
in animals is lost after chronic treatment, it can be restored 
when an acute high dose atorvastatin is delivered immediately 
before ischemia/reperfusion.71 This finding is in agreement 
with the results of the ARMYDA-recapture study. This can 
be explained by the fact that ACS patients have increased 
plaque inflammatory cell density and a greater local produc-
tion of inflammatory cytokines, a situation demanding acute 
suppression afforded by atorvastatin reload.
Other cardioprotective mechanisms include atorvastatin-
induced early increase of endothelial progenitor cell differen-
tiation and subsequent augmentation of circulating endothelial 
progenitors cells with attendant cardioprotective effects,72,73 
inhibition of isoprenoids, which serve as lipid attachments for 
intracellular signaling molecules,74 inhibition of plasminogen 
activator inhibitor I (PAI-I),73 a rapid increase in nitric oxide 
bioavailability75,76 or an activation of specific intracellular 
pathways such as the PI3-K family.77
C o n C l u S I o n S
Thrombosis and inflammation are intrinsically linked in 
the pathogenesis of periprocedural myonecrosis in the setting 
of PCI. Especially in ACS patients, this concept may support 
the utilization of high dose, intensive statin load taking advan-
tage of their acute pleiotropic effects. All patients should be 
treated with a high dose of a potent statin as outpatients, which 
should be continued until the performance of PCI or as soon 
as possible on arrival at the hospital. In patients previously on 
statin therapy, it is not unreasonable to consider upstream use 
of high-dose potent statins by reloading at least 12 hours prior 
to PCI. Statin naive patients may obtain a significant benefit by 
atorvastatin loading even 12 and 2 hours prior to the planned 
PCI, otherwise it would be prudent to postpone elective PCI 
unless the appropriate preparation has been made along with 
aspirin and clopidogrel use.
Current data from four ACS trials and at least four elective 
PCI trials support the notion that use of 80 mg atorvastatin is 
both beneficial and safe. More randomized control trials are 
needed to determine the type, dose and appropriate scheme of 
statin preloading as well as the safety and outcomes of higher 
anti-inflammatory statin doses. Moreover, there is a need to 
assess the efficacy of preprocedural statin loading in various 
clinical settings poorly described as STEMI and emergency/
primary PCI.
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